Still have questions?
Here are some common questions we receive about our kits. For more information, please contact us.
FAQ’s
What is the DxTerity® kit? |
|
Type-1 Interferon (IFN-1) activity is central to how your body defends itself against viruses and pathogens, however persistent over activity has been shown to play a central role in Systemic Lupus Erythematosus (SLE) disease development and progression. It is estimated that more than 50% of SLE patients overexpress IFN-1, and this overexpression has been linked to increased disease severity. DxTerity's IFN-1 Test has been shown to be a possible key prognostic marker for SLE patients developing lupus nephritis. The IFN-1 immune pathway is also a common therapeutic target and the DxTerity IFN-1 Test is being used for therapeutic clinical trial enrollment and monitoring. |
How are collections using the DxTerity kit or the Pax Gene kit different? |
|
Type-1 Interferon (IFN-1) activity is central to how your body defends itself against viruses and pathogens, however persistent over activity has been shown to play a central role in Systemic Lupus Erythematosus (SLE) disease development and progression. It is estimated that more than 50% of SLE patients overexpress IFN-1, and this overexpression has been linked to increased disease severity. DxTerity's IFN-1 Test has been shown to be a possible key prognostic marker for SLE patients developing lupus nephritis. The IFN-1 immune pathway is also a common therapeutic target and the DxTerity IFN-1 Test is being used for therapeutic clinical trial enrollment and monitoring. |
How do I register a kit? |
|
Type-1 Interferon (IFN-1) activity is central to how your body defends itself against viruses and pathogens, however persistent over activity has been shown to play a central role in Systemic Lupus Erythematosus (SLE) disease development and progression. It is estimated that more than 50% of SLE patients overexpress IFN-1, and this overexpression has been linked to increased disease severity. DxTerity's IFN-1 Test has been shown to be a possible key prognostic marker for SLE patients developing lupus nephritis. The IFN-1 immune pathway is also a common therapeutic target and the DxTerity IFN-1 Test is being used for therapeutic clinical trial enrollment and monitoring. |
When and how will I receive test results? |
|
Type-1 Interferon (IFN-1) activity is central to how your body defends itself against viruses and pathogens, however persistent over activity has been shown to play a central role in Systemic Lupus Erythematosus (SLE) disease development and progression. It is estimated that more than 50% of SLE patients overexpress IFN-1, and this overexpression has been linked to increased disease severity. DxTerity's IFN-1 Test has been shown to be a possible key prognostic marker for SLE patients developing lupus nephritis. The IFN-1 immune pathway is also a common therapeutic target and the DxTerity IFN-1 Test is being used for therapeutic clinical trial enrollment and monitoring. |
How can results be used to help patients? |
|
Type-1 Interferon (IFN-1) activity is central to how your body defends itself against viruses and pathogens, however persistent over activity has been shown to play a central role in Systemic Lupus Erythematosus (SLE) disease development and progression. It is estimated that more than 50% of SLE patients overexpress IFN-1, and this overexpression has been linked to increased disease severity. DxTerity's IFN-1 Test has been shown to be a possible key prognostic marker for SLE patients developing lupus nephritis. The IFN-1 immune pathway is also a common therapeutic target and the DxTerity IFN-1 Test is being used for therapeutic clinical trial enrollment and monitoring. |
What safeguards has DxTerity put in place to protect health information? |
|
Type-1 Interferon (IFN-1) activity is central to how your body defends itself against viruses and pathogens, however persistent over activity has been shown to play a central role in Systemic Lupus Erythematosus (SLE) disease development and progression. It is estimated that more than 50% of SLE patients overexpress IFN-1, and this overexpression has been linked to increased disease severity. DxTerity's IFN-1 Test has been shown to be a possible key prognostic marker for SLE patients developing lupus nephritis. The IFN-1 immune pathway is also a common therapeutic target and the DxTerity IFN-1 Test is being used for therapeutic clinical trial enrollment and monitoring. |